Business Context and Reporting Period
Company: Prana Biotechnology Limited (Note: Request metadata listed "Alterity Therapeutics," but the filing text identifies the registrant as Prana Biotechnology Limited).
Reporting Period: Year ended June 30, 2012.
Filing Date: October 2, 2012 (Form 6-K).
Business Overview: Prana is a biotechnology company focused on developing therapies for neurodegenerative disorders, specifically Alzheimer's Disease (AD), Huntington's Disease (HD), and Parkinson's Disease (PD). The company's lead compound, PBT2, is a Metal Protein Attenuating Compound (MPAC) designed to target the underlying disease processes involving metal-protein interactions.
Key Financial Metrics
| Metric | 2012 (AUD) | 2011 (AUD) |
|---|---|---|
| Revenue from Ordinary Activities | $186,664 | $156,135 |
| Other Income (Grants & Tax Refunds) | $2,340,851 | $6,785 |
| Total Income | $2,527,515 | $162,920 |
| Net Loss | $(5,239,469) | $(6,431,185) |
| Loss Per Share (Basic & Diluted) | $(1.82) cents | $(2.60) cents |
| Cash and Cash Equivalents (Year End) | $5,636,469 | $8,838,245 |
| Net Operating Cash Flow | $(6,845,906) | $(4,558,147) |
| Total Assets | $7,341,868 | $9,010,952 |
| Total Liabilities | $1,718,421 | $2,079,750 |
| Net Assets | $5,623,447 | $6,931,202 |
Debt and Liquidity: The company has no traditional debt but holds a Convertible Promissory Note of approximately $299,012 (AUD) to the Alzheimer's Drug Discovery Foundation (ADDF). Liquidity is supported by cash reserves of $5.6 million and an "at-the-market" (ATM) equity facility.
Material Changes vs. Prior Period
- Improved Net Loss: The net loss decreased by approximately $1.2 million (18.5%) compared to the prior year, primarily due to a significant increase in "Other Income."
- Grant and Tax Income: Other income surged from $6,785 in 2011 to $2.34 million in 2012. This was driven by a $2.24 million R&D Tax Concession and a $93,514 grant from the Michael J. Fox Foundation.
- Increased R&D Expenses: Research and development expenses rose by 53% to $4.23 million (from $2.76 million) to support the initiation of Phase II clinical trials.
- Cash Burn: Cash reserves decreased by $3.2 million, reflecting higher operational outflows despite the tax refund.
Guidance, Outlook, and Risks
Clinical Pipeline Progress
- Alzheimer's Disease (IMAGINE Trial): A 12-month Phase II trial in 40 patients with prodromal/mild AD is underway in Melbourne. It utilizes PET imaging to measure beta-amyloid burden. Top-line results are expected in the second half of 2013.
- Huntington's Disease (Reach2HD Trial): A 6-month Phase IIa trial in 100 patients across the US and Australia is recruiting. It assesses cognitive, motor, and behavioral changes. Top-line results are expected in the second half of 2013.
- Parkinson's Disease (PBT434): Pre-clinical studies funded by the Michael J. Fox Foundation are complete. The company aims to file an IND application by the end of 2013 to commence clinical studies in 2014.
Management Commentary
Management expresses confidence in the PBT2 therapeutic strategy, citing its unique mechanism of targeting metal-protein interactions. The appointment of Professor Rudy Tanzi as Chief Scientific Advisor reinforces the company's scientific credibility.
Risks and Contingencies
- Funding Dependency: The company is in a pre-revenue stage and relies on equity raises and grants. The "Going Concern" basis is predicated on the successful raising of additional funds to complete clinical trials.
- Clinical Trial Risk: Success is contingent on positive outcomes from the IMAGINE and Reach2HD trials. Failure to meet endpoints would significantly impact the company's value and future funding prospects.
- Contractual Commitments: The company has committed approximately $7.5 million for the HD trial and $0.7 million for the AD trial. These contracts can be terminated with 30 days' notice without penalty.
Key Facts for Investor Verification
- Cash Runway: Verify the current cash balance against the $7.5 million+ committed expenditure for ongoing clinical trials to assess immediate funding needs.
- ATM Facility Status: Confirm the volume of shares sold under the "at-the-market" facility since the reporting date (Note 25 indicates $1.98 million raised post-year-end) and the remaining capacity.
- Trial Recruitment Rates: Monitor the recruitment progress of the IMAGINE and Reach2HD trials to ensure they remain on track for the projected H2 2013 data readouts.
- Grant Conditions: Review the terms of the ADDF Convertible Promissory Note and the Michael J. Fox Foundation grant to understand any performance milestones or conversion triggers.
- Shareholder Dilution: Assess the impact of the 32.7 million options and warrants currently on issue, many with low or zero exercise prices, on potential future dilution.